2-Bromo-2′-fluoroacetophenone | CAS:655-15-2

We serve 2-Bromo-2′-fluoroacetophenone CAS:655-15-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-2'-fluoroacetophenone

Chemical Name:2-Bromo-2'-fluoroacetophenone
CAS.NO:655-15-2
Synonyms:2-Bromo-2'-fluoroacetophenone
2-Fluorophenacyl bromide;
2'-fluoro-bromoacetophenone
2-Bromo-2-fluoroacetophenone
2'-fluoro-2-bromoacetophenone
Molecular Formula:C8H6BrFO
Molecular Weight:217.03500
 
Physical and Chemical Properties:
Density:1.568
Melting point:25-27ºC
Boiling point:83-85ºC
Flash point:98.6ºC
Index of Refraction:1.587
 
Specification:
Appearance:White to light brown powder
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2-Bromo-2′-fluoroacetophenone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2′-fluoro-2-bromoacetophenone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2′-fluoro-2-bromoacetophenone Use and application,2′-fluoro-2-bromoacetophenone technical grade,usp/ep/jp grade.


Related News: Fears over the continuing spread of coronavirus have also fueled resentment and discrimination. Some have become outcasts in their own country, shunned by hotels, neighbors and — in some areas — placed under controversial quarantine measures.tert-butyl N-[(3R)-piperidin-3-yl]carbamate manufacturer In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.3,4-Difluorobenzyl Bromide supplier In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.2-Amino-9,9-dimethylfluorene vendor In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.